2,2-dimethyl-propanoic acid 3,4-dihydro-4-hydroxy-3-(4-methoxyphenyl)-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]-2H-1-benzopyran-7-yl ester | 444643-87-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 2,2-dimethyl-propanoic acid 3,4-dihydro-4-hydroxy-3-(4-methoxyphenyl)-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]-2H-1-benzopyran-7-yl ester
• 英文别名: [4-Hydroxy-3-(4-methoxyphenyl)-4-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-2,3-dihydrochromen-7-yl] 2,2-dimethylpropanoate
• CAS: 444643-87-2
• 化学式: C₃₅H₄₃NO₆
• 分子量: 573.73
• InChiKey: SVLCBAXPXIFJQF-UHFFFAOYSA-N

物化性质

• 沸点：
  700.7±60.0 °C(Predicted)
• 密度：
  1.169±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  42
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  77.5
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-propanoic acid 3,4-dihydro-4-hydroxy-3-(4-methoxyphenyl)-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]-2H-1-benzopyran-7-yl ester 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 以70%的产率得到3,4-dihydro-3-(4-methoxyphenyl)-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]-2H-1-benzopyran-4,7-diol
  参考文献：
  名称：

  Synthesis, pharmacological evaluation, and structure–activity relationships of benzopyran derivatives with potent SERM activity

  摘要：

  The synthesis, binding affinity for estrogen receptor subtypes (ERalpha and ERbeta) and pharmacological activity on rat uterus of a new class of potent ligands, characterized by a 3-phenylbenzopyran scaffold with a basic side chain in position 4, are reported. Some of these compounds, endowed with very high receptor affinity, showed potent inhibition of agonist-stimulated uterine growth, with no or limited proliferative effect. Binding affinity mostly depended on the nature and position of substituents at the 3-phenyl ring, while the uterine activity seems to be affected by basic chain length. Compound 9c (CHF4227) showed excellent binding affinity and antagonist activity on the uterus. The docking of benzopyran derivatives explained the structure-affinity relationships observed for 3-phenyl substitution: a small, hydrophobic 4'-substituent could interact with a small accessory binding cavity, while di-substitution at 4' and 3' led to some ERalpha selectivity. This selectivity can be ascribed to differences in amino acid composition and side chain conformation in the region accommodating the 3-phenyl ring at human ERalpha and ERbeta ligand-binding domain. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.015
• 作为产物：
  描述：

  2,2-dimethyl-propanoic acid 3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2H-1-benzopyran-7-yl ester 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 magnesium 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 、 丙酮 为溶剂， -20.0~20.0 ℃ 、344.74 kPa 条件下， 生成 2,2-dimethyl-propanoic acid 3,4-dihydro-4-hydroxy-3-(4-methoxyphenyl)-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]-2H-1-benzopyran-7-yl ester
  参考文献：
  名称：

  Synthesis, pharmacological evaluation, and structure–activity relationships of benzopyran derivatives with potent SERM activity

  摘要：

  The synthesis, binding affinity for estrogen receptor subtypes (ERalpha and ERbeta) and pharmacological activity on rat uterus of a new class of potent ligands, characterized by a 3-phenylbenzopyran scaffold with a basic side chain in position 4, are reported. Some of these compounds, endowed with very high receptor affinity, showed potent inhibition of agonist-stimulated uterine growth, with no or limited proliferative effect. Binding affinity mostly depended on the nature and position of substituents at the 3-phenyl ring, while the uterine activity seems to be affected by basic chain length. Compound 9c (CHF4227) showed excellent binding affinity and antagonist activity on the uterus. The docking of benzopyran derivatives explained the structure-affinity relationships observed for 3-phenyl substitution: a small, hydrophobic 4'-substituent could interact with a small accessory binding cavity, while di-substitution at 4' and 3' led to some ERalpha selectivity. This selectivity can be ascribed to differences in amino acid composition and side chain conformation in the region accommodating the 3-phenyl ring at human ERalpha and ERbeta ligand-binding domain. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.015

文献信息

• 2H-1-benzopyran derivatives processes for their preparation and pharmaceutical compositions thereof
  申请人：——

  公开号：US20040106595A1

  公开（公告）日：2004-06-03

  2H-1-Benzopyran derivatives, processes for their preparation and use thereof for the preparation of pharmaceutical compositions for the prevention and treatment of postmenopausal pathologies.

  2H-1-苯并吡喃衍生物，其制备方法以及将其用于制备预防和治疗绝经后病理的药物组合物的用途。
• [EN] 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] DERIVES DE 2H-1-BENZOPYRAN, PROCEDES DE PREPARATION DE CES DERNIERS ET COMPOSITIONS PHARMACEUTIQUES DANS LESQUELS ILS ENTRENT
  申请人：CHIESI FARMA SPA

  公开号：WO2002059113A1

  公开（公告）日：2002-08-01

  2H-1-Benzopyran derivatives, processes for their preparation and use thereof for the preparation of pharmaceutical compositions for the prevention and treatment of postmenopausal pathologies.

  2H-1-苯并吡喃衍生物，其制备方法以及用于制备预防和治疗绝经后病理学的药物组合物的用途。
• 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：EP1281710A1

  公开（公告）日：2003-02-05

  2H-1-benzopyran derivatives, processes for their preparation and use thereof for the preparation of pharmaceutical compositions for the prevention and treatment of postmenopausal pathologies.

  2H-1-苯并吡喃衍生物、其制备工艺及其在制备预防和治疗绝经后病症的药物组合物中的用途。
• 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：EP1355906A1

  公开（公告）日：2003-10-29
• US6951883B2
  申请人：——

  公开号：US6951883B2

  公开（公告）日：2005-10-04